Alpha‑9 Oncology

Alpha‑9 Oncology develops targeted radiopharmaceuticals for cancer, using bespoke molecules to deliver radiation precisely to tumors while sparing tissue.
Domain
Healthcare
Status
Current Private Investment
Stage of Initial Investment
Series C
Initial Investment Year
2024
Alpha9 Portco Hover Image2